Navigation Links
Campbell Alliance Announces Windhover Top 10 Oncology Projects for 2011
Date:11/29/2011

RALEIGH, N.C., Nov. 29, 2011 /PRNewswire/ -- Campbell Alliance, an inVentiv Health company and the leading management consulting firm specializing in the pharmaceutical and biotech industry, today announced the assets chosen for the 2011 Top 10 Most Licensable Oncology Projects to Watch.  Selected projects will be discussed in more detail at the upcoming Windhover Therapeutic Area Partnerships conference (http://www.tapartnerships.com) in Boston, November 30 through December 2.

Narrowed from a field of over 1,700 oncology assets using a strict set of judging criteria, the selected projects represent what are considered the most attractive licensable oncology opportunities the industry has to offer.  Specifically, the selection team focused on what are considered "hot areas" in oncology:  those with transformational, nascent therapies where the potential for differentiation is high.  Conjugated antibody, cancer metabolism, and immuno-oncology technologies dominated the list this year.

"Our approach this year was to look at differentiated molecular pathways and technologies," said Jonathon Fendelman, Senior Practice Executive at Campbell Alliance.
"While these targeted approaches tend to address smaller patient populations initially, a great deal of potential exists for add-on indications, which makes them attractive licensing opportunities.  Further, strong differentiation raises the likelihood of reimbursement post-approval, which is key in an increasingly payer-driven market."
2011 Top 10 Most Licensable Oncology Projects to Watch
CompanyAsset/CompoundLocationWebsiteAdvaxis

ADXS-HPV

US/New Jersey

www.advaxis.comAltor

ALT-801

US/Florida

www.altorbioscience.comAveo

Ficlatuzumab

US/Massachusetts

www.aveopharma.comBiotest AG

BT-062

Germany

www.biotest.comCelldex

CDX-011

US/Massachusetts

www.celldextherapeutics.comEndocyte

EC145

US/Indiana

www.endocyte.comImmunoCellular Therapeutics

ICT-107

US/California

www.imuc.comImmune System Therapeutics 

MDX 1097

Australia

www.istl.com.auNeogenix Oncology

Ensituximab/NPC-1C

US/New York

www.neogenix.comRuga

STF-31

US/California

www.rugacorp.comCampbell Alliance has served as advisor for the oncology track of the Therapeutic Area Partnerships event since 2007.  More information on Campbell Alliance's Top 10 Oncology Projects can be found at http://www.campbellalliance.com/OncTop10.

Windhover originally announced the full list of companies selected as part of the Therapeutic Area Partnerships conference on November 1.  The list included assets from each of several therapeutic areas:  cardiovascular/metabolic, oncology, neuroscience, infectious diseases, and inflammatory/autoimmune, plus a "hot space" category, including ophthalmology, orphan diseases, and women's health.

About Campbell Alliance
Campbell Alliance is the Consulting business segment of inVentiv Health, a leading global provider of best-in-class clinical, commercial, and consulting services to companies seeking to accelerate performance.  Campbell Alliance is the leading management consulting firm specializing in the pharmaceutical and biotechnology industry.  The firm's clients include all of the world's top-20 pharmaceutical companies, as well as numerous emerging and midsize firms. Campbell Alliance is organized into practice areas, each specializing in a critical industry function: Brand Management, Business Development, Clinical Development, Pricing and Market Access, Medical Affairs, and Sales.  From its locations in Raleigh, NC, Parsippany, NJ, Los Angeles, San Francisco, Chicago, Boston, Philadelphia, New York City, Atlanta, and Zug, Switzerland, the firm serves clients throughout North America, Europe, and Japan. For more information on Campbell Alliance, please visit http://www.campbellalliance.com.   

 

 CONTACT:James Forte

Director, Public and Media Relations

Campbell Alliance

919-844-7100, extension 7195

jforte@campbellalliance.com
'/>"/>

SOURCE Campbell Alliance
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. WorldHeart Appoints Dr. John Campbell Woodard as Senior Vice President of Scientific Affairs
2. Tunnell Consulting Forms Strategic Alliance With Ireland-Based Campbell Informatics
3. Campbell Alliance Announces Executive Promotions and Organizational Changes
4. Nader Naeymi-Rad Appointed CEO of Campbell Alliance
5. Alliance Pharmaceutical Corp. Updates Oxygent(TM) Clinical Development Plan
6. Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe
7. Lung Cancer Alliance Commends NCCN on Screening Guidelines
8. Lung Cancer Alliance Hails Announcement of New Erbitux(R) Data
9. Alliance Pharmaceutical Corp. Announces Approval of Proposed Actions at Annual Shareholders Meeting
10. Vermillion Renews Strategic Alliance Agreement With Quest Diagnostics, Inc.
11. Ambrx and Merck Serono Expand Collaboration Through ARX424 Multiple Sclerosis Drug Development Alliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... 23, 2017  Directors from Pharma To Market Pty Ltd and ... forces, resulting in the founding of Pharma To Market Pte Ltd, ... Market are pleased to announce their expansion into Asia ... Singapore . The company are delighted to appoint Joelle ... Singapore based entity. Joelle brings with her ...
(Date:2/24/2017)... 24, 2017  Xynomic Pharmaceuticals, Inc., an oncology drug ... has acquired exclusive worldwide rights to develop, manufacture ... inhibitor targeting hematological and solid tumors. ... and 2 clinical trials of Abexinostat in US, ... already been completed, demonstrating that Abexinostat is clinically ...
(Date:2/23/2017)... Südkorea, 23. Februar 2017 LG Innotek hat ... vorgestellt. Die Sterilisationsleistung beträgt das 1,5-fache des 45-mW-Moduls der ... im Bereich zwischen 200 und 280 nm und eignet sich ... indem es ihre DNA zerstört. Das Produkt von LG ... ...
Breaking Medicine Technology:
(Date:2/26/2017)... ... 26, 2017 , ... IndustryArchive.Org . is announcing a new way for ... will now only pay for B.A.N.T. quality sales leads based on the Sellers decision ... the new reality that B2B buyers are controlling the sales process via the Internet ...
(Date:2/26/2017)... Miami, Florida (PRWEB) , ... February 26, 2017 ... ... disease (PD) patients after receiving cognitive rehabilitation, according to a study released today ... already known that cognitive rehabilitation programs are proven to be effective in improving ...
(Date:2/24/2017)... ... February 24, 2017 , ... HealthPostures, ... Go. Core benefits and advantages built into the home office sit stand solution ... and feel. Ability to gain the benefits embedded in the TaskMate Go are ...
(Date:2/24/2017)... ... 24, 2017 , ... WHAT: , The New Jersey Tech ... well as advocacy for the state and region‘s technology businesses, hosted their 2017 ... Council's Innovation Forecast event highlights innovation throughout the region from small to large ...
(Date:2/24/2017)... ... February 24, 2017 , ... The Smart Machine Age is here, and ... that 47 percent of all jobs in the United States may be taken over ... day of the aggressive know-it-all who steamrolls over colleagues is drawing to a close. ...
Breaking Medicine News(10 mins):